Shared on07 May 25Fair value Decreased 0.83%
AnalystLowTarget made no meaningful changes to valuation assumptions.
Loading...
Neuropsychiatric Treatments Will Face Regulatory Setbacks Yet Yield Progress
AnalystLowTarget's Fair Value
US$30.00
0% overvalued intrinsic discount10 Sep
US$30.00
1Y
4.1%7D
8.1%1Y
4.1%7D
8.1%You can edit this narrative until May 12 5:59 AM. Then, changes will post as Updates.